Eupraxia Pharmaceuticals Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 18
Employees
  • Stock Symbol
  • EPRX
Stock Symbol
  • Share Price
  • $3.42
  • (As of Friday Closing)

Eupraxia Pharmaceuticals General Information

Description

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to approved drugs. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.

Contact Information

Formerly Known As
Plaza Capital Partners
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
TSE
Primary Office
  • 201-2067 Cadboro Bay Road
  • Victoria, British Columbia V8R 5G4
  • Canada
+1 (250) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eupraxia Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.42 $3.55 $3.12 - $6.12 $45.9M 12.9M 18.4K -$0.96

Eupraxia Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 62,946
Revenue 0 0 0 0
EBITDA (6,691) (1,500) (4,209) (11,235)
Net Income (8,094) (2,979) (5,406) (10,206)
Total Assets 25,795 1,140 2,515 2,136
Total Debt 5,035 10,013 9,138 2,785
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eupraxia Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eupraxia Pharmaceuticals‘s full profile, request access.

Request a free trial

Eupraxia Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered,
Drug Delivery
Victoria, Canada
18 As of 2021
000.00
00.00 0000-00-00
00000000 000.00

0000000

illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
000000000000000
South San Francisco, CA
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

00000 00

piscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim ve
000000000000000
Boston, MA
000 As of 0000
0000
0.00 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eupraxia Pharmaceuticals Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Portola Pharmaceuticals Formerly VC-backed South San Francisco, CA 000 00000 000000&0 00000
00000 000000000000 Formerly VC-backed Boston, MA 000 0000 000000&0 0000
0000000 Formerly VC-backed South San Francisco, CA 00 00000 000000 - 000 00000
000 (0000000000000 Venture Capital-Backed Surrey, Canada 00 000.00 0000000000 0 000.00
0000000 0000000000 Formerly VC-backed Cambridge, United Kingdom 00 00000 000000000 00000
You’re viewing 5 of 8 competitors. Get the full list »

Eupraxia Pharmaceuticals Executive Team (10)

Name Title Board Seat Contact Info
James Helliwell MD Chief Executive Officer & Board Member
Alex Rothwell Chief Operating Officer
Amanda Malone Ph.D Chief Scientific Officer & Founder
Ash Bassett Director, Finance
Vik Peck Vice President, Program Management
You’re viewing 5 of 10 executive team members. Get the full list »

Eupraxia Pharmaceuticals Board Members (6)

Name Representing Role Since
James Helliwell MD Eupraxia Pharmaceuticals Chief Executive Officer & Board Member 000 0000
John Montalbano Self Board Member 000 0000
Michael Wilmink MD Self Board Member 000 0000
Paul Geyer Self Board Member 000 0000
Richard Glickman Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Eupraxia Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eupraxia Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Eupraxia Pharmaceuticals‘s full profile, request access.

Request a free trial